Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 26.2% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Exact Sciences (EXAS) a New Buy Stock
Exact Sciences (EXAS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Continue to Hold EXAS Sciences Stock in Your Portfolio?
EXAS rides on strong Cologuard and Oncotype DX growth, but rising costs and high debt may test its staying power.
EXAS Stock Up on Q1 Earnings & Revenue Beat, 2025 Sales View Raised
Exact Sciences ends the first quarter of 2025 on a solid note.
Exact Sciences Corporation (EXAS) Q1 2025 Earnings Call Transcript
Exact Sciences Corporation. (NASDAQ:EXAS ) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ET Company Participants Derek Leckow - Vice President, Investor Relations Kevin Conroy - Chairman and Chief Executive Officer Aaron Bloomer - Chief Financial Officer Brian Baranick - General Manager, Precision Oncology Conference Call Participants Tycho Peterson - Jefferies Catherine Schulte - Baird Brandon Couillard - Wells Fargo Colleen Babington - Wolfe Research Patrick Donnelly - Citi Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Puneet Souda - Leerink Partners Subu Nambi - Guggenheim Andrew Brackmann - William Blair Luke Sergott - Barclays.
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.50 per share a year ago.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
